J
James Yarmolinsky
Researcher at University of Bristol
Publications - 51
Citations - 5218
James Yarmolinsky is an academic researcher from University of Bristol. The author has contributed to research in topics: Mendelian randomization & Medicine. The author has an hindex of 13, co-authored 36 publications receiving 2010 citations. Previous affiliations of James Yarmolinsky include Universidade Federal do Rio Grande do Sul & Medical Research Council.
Papers
More filters
Journal ArticleDOI
The MR-Base platform supports systematic causal inference across the human phenome
Gibran Hemani,Jie Zheng,Benjamin Elsworth,Kaitlin H Wade,Valeriia Haberland,Denis Baird,Charles Laurin,Stephen Burgess,Jack Bowden,Ryan Langdon,Vanessa Y Tan,James Yarmolinsky,Hashem A Shihab,Nicholas J. Timpson,David M. Evans,David M. Evans,Caroline L Relton,Richard M. Martin,George Davey Smith,Tom R. Gaunt,Philip C Haycock +20 more
TL;DR: MR-Base is a platform that integrates a curated database of complete GWAS results (no restrictions according to statistical significance) with an application programming interface, web app and R packages that automate 2SMR, and includes several sensitivity analyses for assessing the impact of horizontal pleiotropy and other violations of assumptions.
Peer ReviewDOI
Author response: The MR-Base platform supports systematic causal inference across the human phenome
Gibran Hemani,Jie Zheng,Benjamin Elsworth,Kaitlin H Wade,Valeriia Haberland,Denis Baird,Charles Laurin,Stephen Burgess,Jack Bowden,Ryan Langdon,Vanessa Y Tan,James Yarmolinsky,Hashem A Shihab,Nicholas J. Timpson,David M. Evans,David M. Evans,Caroline L Relton,Richard M. Martin,George Davey Smith,Tom R. Gaunt,Philip C Haycock +20 more
Journal ArticleDOI
Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement
Veronika Skrivankova,Rebecca C Richmond,Benjamin Woolf,James Yarmolinsky,Neil M Davies,Neil M Davies,Sonja A. Swanson,Tyler J. VanderWeele,Julian P T Higgins,Nicholas J. Timpson,Niki Dimou,Claudia Langenberg,Claudia Langenberg,Robert M. Golub,Elizabeth Loder,Elizabeth Loder,Valentina Gallo,Valentina Gallo,Valentina Gallo,Anne Tybjærg-Hansen,George Davey Smith,Matthias Egger,Matthias Egger,Matthias Egger,J. Brent Richards,J. Brent Richards +25 more
TL;DR: The STROBE-MR Statement as discussed by the authors provides guidelines for reporting Mendelian Randomization (MR) studies and provides a set of guidelines to improve the reporting of these studies.
Journal ArticleDOI
Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.
Jie Zheng,Valeriia Haberland,Denis Baird,Venexia M Walker,Philip C Haycock,Mark R. Hurle,Alex Gutteridge,Pau Erola,Yi Liu,Shan Luo,Shan Luo,Jamie Robinson,Tom G. Richardson,James R Staley,James R Staley,Benjamin Elsworth,Stephen Burgess,Benjamin B. Sun,John Danesh,Heiko Runz,Joseph C. Maranville,Hannah M. Martin,James Yarmolinsky,Charles Laurin,Michael V. Holmes,Jimmy Z. Liu,Karol Estrada,Rita Santos,Linda McCarthy,Dawn M. Waterworth,Matthew R. Nelson,George Davey Smith,Adam S. Butterworth,Gibran Hemani,Robert A. Scott,Tom R. Gaunt +35 more
TL;DR: Evaluation of data from historic drug development programs showed that target-indication pairs with MR and colocalization support were more likely to be approved, evidencing the value of this approach in identifying and prioritizing potential therapeutic targets.
Posted ContentDOI
MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations
Gibran Hemani,Jie Zheng,Kaitlin H Wade,Charles Laurin,Benjamin Elsworth,Stephen Burgess,Jack Bowden,Ryan Langdon,Tan,James Yarmolinsky,Hashem A. Shihab,Nicholas J. Timpson,David M. Evans,Caroline L Relton,Richard M. Martin,G Davey Smith,Tom R. Gaunt,P Haycock +17 more
TL;DR: While the analysis provides evidence that reducing LDL-cholesterol, lipoprotein(a) or triglyceride levels reduce coronary disease risk, it also suggests causal effects on a number of other non-vascular outcomes, indicating potential for adverse-effects or drug repositioning of lipid-lowering therapies.